December 2020
BJC Staff
The patients who developed cardiotoxicity were treated with beta blockers (carvedilol), angiotensin-converting enzyme inhibitors (enalapril) or angiotensin receptor blockers (valsartan), aldosterone antagonists (eplerenone), digitalis and diuretics (furosemide), as needed. When patients remained symptomatic and met the PARADIGM-HF inclusion criteria, sacubitril/valsartan was started instead of enalapril or valsartan. Results showed that sacubitril/valsartan therapy produced an improvement in ventricular remodelling, diastolic dysfunction, and on symptoms, reflected in the New York Heart Association class and the six-minute walk test. The auth
July 2019 Br J Cardiol 2019;26(suppl1):S3 doi:10.5837/bjc.2019.s01
Pardeep S Jhund, John J V McMurray
The PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) study is the key randomised-controlled trial that underpins the clinical use of sacubitril/valsartan, which demonstrated significantly improved clinical outcomes in patients with HFrEF, in comparison with angiotensin-converting enzyme (ACE) inhibition.1 Patients with HFrEF in the routine-care setting represent a clinically heterogeneous population, with a high incidence of comorbidities. Our first article dives deep into the PARADIGM-HF data, and presents the results of key subgroup analyses that support the use o
July 2019 Br J Cardiol 2019;26(suppl 1):S20-S21 doi:10.5837/bjc.2019.s05
Pauline Rouse
Introduction Following publication of the PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial,1 and being aware of the anticipated National Institute for Health and Care Excellence (NICE) approval of sacubitril/valsartan, this gave the impetus to ensure our patients could have access to this medication as soon as it was NICE approved. Medway has a population of 280,000. The heart failure team at Medway Community Healthcare was established in 2003 and has grown and developed since then as part of the community cardiology team (also providing cardiac rehabilitation
July 2019 Br J Cardiol 2019;26(suppl 1):S22–S23 doi:10.5837/bjc.2019.s06
Edith Donnelly, Carol Patton
Background The Southern Health and Social Care Trust (SHSCT) in Northern Ireland has a nurse-led heart failure (HF) service, with seven band 7 heart failure nurse specialists (HFNS) serving a total of about 1,500 patients. All but two of the nurses are non-medical prescribers. The service is community-based with hospital in-reach, with each nurse managing a geographically defined caseload. This model allows patients with HF to be reviewed by a HFNS in either a domiciliary, clinic or acute setting. The nurses have access to, and support from, consultant cardiologists, renal consultants, GPs and a cardiology pharmacist, and also have access to
August 2017 Br J Cardiol 2017;24:(3) Online First
BJC Staff, Dr Richard Crawley, Dr Brian Halliday, Dr Rosita Zakeri
Landmark trials in heart failure – 30 years from CONSENSUS With 2017 marking the 30th year since the publication of CONSENSUS,1 which first reported a reduction in mortality with enalapril versus placebo in patients with advanced heart failure (HF), the BCS held a dedicated session to review the seminal clinical trials and advances in chronic heart failure management in this period. Dr Rosita Zakeri (Royal Brompton Hospital, London) reviewed this session for us and spoke to the BJC afterwards. Rosita Zakeri The era of vasodilator therapy for heart failure began in the 1990s. Professor Karl Swedberg (University of Gothenberg, Sweden) began
May 2012 Br J Cardiol 2012;19:57
BJCardio Staff
Studies involving nearly 6,000 patients with hypertension have shown it lowers blood pressure (BP) significantly more than ramipril, valsartan and olmesartan medoxomil when compared at their maximum doses. It also maintains BP lowering over a 24-hour period. Data on the new compound were presented by Professor Luis Ruilope, (Hospital 12 de Octubre, Madrid, Spain) at a Takedasponsored symposium during the 22nd European Society of Hypertension (ESH) meeting, held in London from 26th–28th April recently. In one study with ramipril, azilsartan 80 mg once daily provided a 9/6 mmHg greater reduction in clinic BP than ramipril 10 mg once daily, at
May 2010 Br J Cardiol 2010;17:111-5
BJ Cardio Staff
ACCORD/INVEST: do not aim for normal blood pressure in diabetes patients with CAD The results of two trials comparing intensive versus more conventional blood pressure lowering in patients with diabetes at high cardiovascular risk have suggested that intensive treatment is not necessary and may be harmful in this population. In the ACCORD BP (Action to Control Cardiovascular Risk in Diabetes – Blood Pressure) trial, while intensive blood pressure treatment did reduce the risk of stroke, it failed to reduce the overall risk of cardiovascular events in patients and was associated with an increase in adverse events due to antihypertensive ther
June 2002 Br J Cardiol 2002;9:351-4
Jatin KV Patel and Richard Leaback, on behalf of the POSATIV investigators
No content available
May 2002 Br J Cardiol 2002;9:280-6
Simon W Dubrey
No content available
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits